Arctic Bioscience – New cellular research showing anti-psoriatic effects
Arctic Bioscience are today presenting new research on cells at the EADV congress in Amsterdam. These cellular data show anti-psoriatic effects from phospholipid esters from herring roe oil in immune cells and skin cells. These data contribute to the understanding of how the investigational medicinal product HRO350 could impact psoriasis, and are supportive data to the ongoing clinical development program, where the ongoing phase 2b HeROPA clinical trial in mild-to-moderate psoriasis has a planned read-out later in September/early October 2024.
"We are very pleased to present additional positive cellular data on the anti-psoriatic properties related to our investigational medicine, HRO350. Through these cellular studies, we are increasing our understanding of how HRO350 works", says CEO Christer L. Valderhaug.
The data from the cellular studies show that Phospholipid Esters from Herring Roe can have immunomodulatory anti-psoriatic effects by affecting signaling on the IL-17/23 axis in immune cells and psoriatic skin cell models. This increases the understanding of the potential mode-of-action of HRO350, and are supplementary to cellular data on effects on Specialized Pro-Resolving Mediators (SPMs) in immune cells which were presented in June this year (Ringheim-Bakka 2024) as well as previously published data on inflammatory markers in psoriasis from a clinical study (Petrovic 2023).
“These are exciting data, which show that HRO350 can impact cellular signaling pathways relevant for psoriasis in both primary human immune cells and psoriasis skin cell models. We are proud to have conducted this research in Norway, in collaboration with Nofima and Møreforsking, and we are grateful for the support from the Research Council of Norway”, says Medical Director Runhild Gammelsæter.
The study was conducted in collaboration with Møreforsking and Nofima, and was supported with a grant from The Research Council of Norway (project nr. 327953, Properties of phospholipids from Herring Roe in Psoriasis).
Reference: Mildenberger J, Solberg N, Østbye TK, Høst V, Petruccelli F, Gammelsæter R, Rønning SB, Pedersen ME. “Phospholipid Esters from Herring Roe promotes SPM biosynthesis in human monocyte-derived macrophages with implications for the treatment of psoriasis”. Poster 3243 at the EADV congress, Amsterdam, September 25-28th, 2024.
The poster will be made available on the IR tab on the company’s webpage.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Christer L. Valderhaug
CEO
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.